190 related articles for article (PubMed ID: 19322210)
1. Deletion 5q in myelodysplastic syndrome: a paradigm for the study of hemizygous deletions in cancer.
Ebert BL
Leukemia; 2009 Jul; 23(7):1252-6. PubMed ID: 19322210
[TBL] [Abstract][Full Text] [Related]
2. Molecular dissection of the 5q deletion in myelodysplastic syndrome.
Ebert BL
Semin Oncol; 2011 Oct; 38(5):621-6. PubMed ID: 21943668
[TBL] [Abstract][Full Text] [Related]
3. Genetic deletions in AML and MDS.
Ebert BL
Best Pract Res Clin Haematol; 2010 Dec; 23(4):457-61. PubMed ID: 21130407
[TBL] [Abstract][Full Text] [Related]
4. Deletion 5q MDS: molecular and therapeutic implications.
Komrokji RS; Padron E; Ebert BL; List AF
Best Pract Res Clin Haematol; 2013 Dec; 26(4):365-75. PubMed ID: 24507813
[TBL] [Abstract][Full Text] [Related]
5. Loss of 5q in myeloid malignancies - A gain in understanding of biological and clinical consequences.
Venugopal S; Mascarenhas J; Steensma DP
Blood Rev; 2021 Mar; 46():100735. PubMed ID: 32736878
[TBL] [Abstract][Full Text] [Related]
6. Changes in RPS14 expression levels during lenalidomide treatment in Low- and Intermediate-1-risk myelodysplastic syndromes with chromosome 5q deletion.
Oliva EN; Cuzzola M; Nobile F; Ronco F; D'Errigo MG; Laganà C; Morabito F; Galimberti S; Cortelezzi A; Aloe Spiriti MA; Specchia G; Poloni A; Breccia M; Ghio R; Finelli C; Iacopino P; Alimena G; Latagliata R
Eur J Haematol; 2010 Sep; 85(3):231-5. PubMed ID: 20491881
[TBL] [Abstract][Full Text] [Related]
7. Coordinate loss of a microRNA and protein-coding gene cooperate in the pathogenesis of 5q- syndrome.
Kumar MS; Narla A; Nonami A; Mullally A; Dimitrova N; Ball B; McAuley JR; Poveromo L; Kutok JL; Galili N; Raza A; Attar E; Gilliland DG; Jacks T; Ebert BL
Blood; 2011 Oct; 118(17):4666-73. PubMed ID: 21873545
[TBL] [Abstract][Full Text] [Related]
8. Molecular cytogenetic delineation of the critical deleted region in the 5q- syndrome.
Jaju RJ; Boultwood J; Oliver FJ; Kostrzewa M; Fidler C; Parker N; McPherson JD; Morris SW; Müller U; Wainscoat JS; Kearney L
Genes Chromosomes Cancer; 1998 Jul; 22(3):251-6. PubMed ID: 9624537
[TBL] [Abstract][Full Text] [Related]
9. Cytogenetic features of 5q deletion and 5q- syndrome in myelodysplastic syndrome in Korea; marker chromosomes proved to be chromosome 5 with interstitial deletion by fluorescence in situ hybridization.
Lee HR; Oh B; Hong DS; Zang DY; Yoon HJ; Kim HJ; Kim I; Ahn JS; Cheong JW; Lee KA; Cho KS; Lee MH; Bang SM; Kim TY; Yun YM; Min YH; Lee YK; Lee DS;
Cancer Genet Cytogenet; 2010 Dec; 203(2):193-202. PubMed ID: 21156233
[TBL] [Abstract][Full Text] [Related]
10. Polymerase chain reaction-based diagnosis of del (5q) in acute myeloid leukemia and myelodysplastic syndrome identifies a minimal deletion interval.
Horrigan SK; Westbrook CA; Kim AH; Banerjee M; Stock W; Larson RA
Blood; 1996 Oct; 88(7):2665-70. PubMed ID: 8839861
[TBL] [Abstract][Full Text] [Related]
11. A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide.
Wei S; Chen X; Rocha K; Epling-Burnette PK; Djeu JY; Liu Q; Byrd J; Sokol L; Lawrence N; Pireddu R; Dewald G; Williams A; Maciejewski J; List A
Proc Natl Acad Sci U S A; 2009 Aug; 106(31):12974-9. PubMed ID: 19470455
[TBL] [Abstract][Full Text] [Related]
12. 5q- myelodysplastic syndromes: chromosome 5q genes direct a tumor-suppression network sensing actin dynamics.
Eisenmann KM; Dykema KJ; Matheson SF; Kent NF; DeWard AD; West RA; Tibes R; Furge KA; Alberts AS
Oncogene; 2009 Oct; 28(39):3429-41. PubMed ID: 19597464
[TBL] [Abstract][Full Text] [Related]
13. Allelic loss of IRF1 in myelodysplasia and acute myeloid leukemia: retention of IRF1 on the 5q- chromosome in some patients with the 5q- syndrome.
Boultwood J; Fidler C; Lewis S; MacCarthy A; Sheridan H; Kelly S; Oscier D; Buckle VJ; Wainscoat JS
Blood; 1993 Nov; 82(9):2611-6. PubMed ID: 8219215
[TBL] [Abstract][Full Text] [Related]
14. Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation.
Liu TX; Becker MW; Jelinek J; Wu WS; Deng M; Mikhalkevich N; Hsu K; Bloomfield CD; Stone RM; DeAngelo DJ; Galinsky IA; Issa JP; Clarke MF; Look AT
Nat Med; 2007 Jan; 13(1):78-83. PubMed ID: 17159988
[TBL] [Abstract][Full Text] [Related]
15. Submicroscopic deletions in 5q- associated malignancies.
Crescenzi B; La Starza R; Romoli S; Beacci D; Matteucci C; Barba G; Aventin A; Marynen P; Ciolli S; Nozzoli C; Martelli MF; Mecucci C
Haematologica; 2004 Mar; 89(3):281-5. PubMed ID: 15020265
[TBL] [Abstract][Full Text] [Related]
16. 5q- syndrome.
Boultwood J; Pellagatti A; Wainscoat JS
Curr Pharm Des; 2012; 18(22):3180-3. PubMed ID: 22571696
[TBL] [Abstract][Full Text] [Related]
17. A critical review of the molecular pathophysiology of lenalidomide sensitivity in 5q - myelodysplastic syndromes.
Voutsadakis IA; Cairoli A
Leuk Lymphoma; 2012 May; 53(5):779-88. PubMed ID: 21955212
[TBL] [Abstract][Full Text] [Related]
18. The molecular pathogenesis of the myelodysplastic syndromes.
Pellagatti A; Boultwood J
Eur J Haematol; 2015 Jul; 95(1):3-15. PubMed ID: 25645650
[TBL] [Abstract][Full Text] [Related]
19. Identification of RPS14 as a 5q- syndrome gene by RNA interference screen.
Ebert BL; Pretz J; Bosco J; Chang CY; Tamayo P; Galili N; Raza A; Root DE; Attar E; Ellis SR; Golub TR
Nature; 2008 Jan; 451(7176):335-9. PubMed ID: 18202658
[TBL] [Abstract][Full Text] [Related]
20. A cryptic deletion in 5q31.2 provides further evidence for a minimally deleted region in myelodysplastic syndromes.
MacKinnon RN; Kannourakis G; Wall M; Campbell LJ
Cancer Genet; 2011 Apr; 204(4):187-94. PubMed ID: 21536236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
